14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BOLD vs VYGR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Voyager Therapeutics, Inc. (VYGR) on higher Unified Composite conviction (36.8/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while VYGR wins 3–2 across the 6-pillar growth and valuation breakdown. BOLD trades at $2.32 (N/M Forward P/E, 0.0% operating margin) versus VYGR at $1.53 (8.4x Forward P/E, -436.2% operating margin).
Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -436.2% operating margin) and revenue trajectory (+0.0% vs. -70.0% YoY).
Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile VYGR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs VYGR. Trailing 12-month operating profitability (BOLD 0.0% vs VYGR -436.2%) and valuation multiples (BOLD N/M vs VYGR 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $100.2M market capitalization and -436.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BOLD vs VYGR Key Questions & Quantitative Answers
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Voyager Therapeutics, Inc. (VYGR) on higher Unified Composite conviction (36.8/100 SELL vs. 47.5/100 HOLD) after splitting the core matrix 4–5 (led by Profitability & Quality, Options & Positioning), while VYGR wins 3–2 across the 6-pillar growth and valuation breakdown. BOLD trades at $2.32 (N/M Forward P/E, 0.0% operating margin) versus VYGR at $1.53 (8.4x Forward P/E, -436.2% operating margin). Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -436.2% operating margin) and revenue trajectory (+0.0% vs. -70.0% YoY). Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile VYGR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VYGR leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VYGR at -70.0% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -436.2% operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus $25M for VYGR. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VYGR.
VYGR screens cheaper on headline valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VYGR trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus VYGR (-58.9% ROE) capital efficiency.
In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, VYGR carries 130.1% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.49β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.